7 research outputs found

    Hide and seek: how PDFs can conceal New Physics

    Full text link
    The interpretation of LHC data, and the assessment of possible hints of new physics, require the precise knowledge of the proton structure in terms of parton distribution functions (PDFs). We present a systematic methodology designed to determine whether and how global PDF fits might inadvertently 'fit away' signs of new physics in the high-energy tails of the distributions. We showcase a scenario for the High-Luminosity LHC, in which the PDFs may completely absorb such signs of new physics, thus biasing theoretical predictions and interpretations. We discuss strategies to single out the effects in this scenario, and disentangle the inconsistencies that stem from them. Our study brings to light the synergy between the high luminosity programme at the LHC and future low-energy non-LHC measurements of large-xx sea quark distributions. The analysis code used in this work is made public so that any users can test the robustness of the signal associated to a given BSM model against absorption by the PDFs.Comment: 48 pages, 23 figure

    Hide and seek: how PDFs can conceal New Physics

    No full text
    The interpretation of LHC data, and the assessment of possible hints of new physics, require the precise knowledge of the proton structure in terms of parton distribution functions (PDFs). We present a systematic methodology designed to determine whether and how global PDF fits might inadvertently 'fit away' signs of new physics in the high-energy tails of the distributions. We showcase a scenario for the High-Luminosity LHC, in which the PDFs may completely absorb such signs of new physics, thus biasing theoretical predictions and interpretations. We discuss strategies to single out the effects in this scenario, and disentangle the inconsistencies that stem from them. Our study brings to light the synergy between the high luminosity programme at the LHC and future low-energy non-LHC measurements of large-xx sea quark distributions. The analysis code used in this work is made public so that any users can test the robustness of the signal associated to a given BSM model against absorption by the PDFs

    Rilpivirine in HIV-1-positive women initiating pregnancy: to switch or not to switch?

    No full text
    International audienceBackgroundSafety data about rilpivirine use during pregnancy remain scarce, and rilpivirine plasma concentrations are reduced during second/third trimesters, with a potential risk of viral breakthroughs. Thus, French guidelines recommend switching to rilpivirine-free combinations (RFCs) during pregnancy.ObjectivesTo describe the characteristics of women initiating pregnancy while on rilpivirine and to compare the outcomes for virologically suppressed subjects continuing rilpivirine until delivery versus switching to an RFC.MethodsIn the ANRS-EPF French Perinatal cohort, we included women on rilpivirine at conception in 2010–18. Pregnancy outcomes were compared between patients continuing versus interrupting rilpivirine. In women with documented viral suppression (<50 copies/mL) before 14 weeks of gestation (WG) while on rilpivirine, we compared the probability of viral rebound (≥50 copies/mL) during pregnancy between subjects continuing rilpivirine versus those switching to RFC.ResultsAmong 247 women included, 88.7% had viral suppression at the beginning of pregnancy. Overall, 184 women (74.5%) switched to an RFC (mostly PI/ritonavir-based regimens) at a median gestational age of 8.0 WG. Plasma HIV-1 RNA nearest delivery was <50 copies/mL in 95.6% of women. Among 69 women with documented viral suppression before 14 WG, the risk of viral rebound was higher when switching to RFCs than when continuing rilpivirine (20.0% versus 0.0%, P = 0.046). Delivery outcomes were similar between groups (overall birth defects, 3.8/100 live births; pregnancy losses, 2.0%; preterm deliveries, 10.6%). No HIV transmission occurred.ConclusionsIn virologically suppressed women initiating pregnancy, continuing rilpivirine was associated with better virological outcome than changing regimen. We did not observe a higher risk of adverse pregnancy outcomes
    corecore